Cytokine release syndrome and tumor lysis syndrome in a multiple myeloma patient treated with palliative radiotherapy: A case report and review of the literature.
Cytokine release syndrome
Hematology
Leukemia
Multiple myeloma
Radiation oncology
Radiotherapy
Total body irradiation
Tumor lysis syndrome
Journal
Clinical and translational radiation oncology
ISSN: 2405-6308
Titre abrégé: Clin Transl Radiat Oncol
Pays: Ireland
ID NLM: 101713416
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
received:
13
08
2021
revised:
05
11
2021
accepted:
06
11
2021
entrez:
24
11
2021
pubmed:
25
11
2021
medline:
25
11
2021
Statut:
epublish
Résumé
We present the case of a 53-year-old woman treated with analgesic radiotherapy for a multiple myeloma bone lesion of the forearm. After a first fraction of 5 Gray (Gy), she presented with an acute respiratory syndrome with fever a few hours after the treatment. The same symptoms occurred after the second fraction 3 days later. The patient recovered quickly thanks to intravenous hydration and suspension of the radiotherapy. Biological tests revealed a tumor lysis syndrome. We concluded that the clinical symptoms could be defined as cytokine release syndrome. This is the second time in the literature that cytokine release syndrome has been described following radiotherapy. First, we synthesize TLS and radiotherapy to determine how radiotherapy could be a trigger associated with other well-known factors. Furthermore, we discuss radiotherapy and cytokine release syndrome. We present the case of a woman treated with analgesic radiotherapy for a multiple myeloma bone lesion. Following the first and the second treatment fraction, the patient presented with an acute respiratory syndrome with fever and biological tests revealed a tumor lysis syndrome. We concluded that the clinical symptoms could be defined as cytokine release syndrome. Furthermore, we discuss how radiotherapy could be a trigger of cytokine release syndrome and tumor lysis syndrome in association with chemotherapy drugs.
Identifiants
pubmed: 34816023
doi: 10.1016/j.ctro.2021.11.004
pii: S2405-6308(21)00095-1
pmc: PMC8591462
doi:
Types de publication
Case Reports
Langues
eng
Pagination
24-28Informations de copyright
© 2021 The Author(s).
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
J Clin Oncol. 2007 Nov 1;25(31):5047
pubmed: 17971612
Cancer. 1984 Apr 15;53(8):1783-5
pubmed: 6199103
Jpn J Clin Oncol. 2014 May;44(5):435-41
pubmed: 24664944
Ann Oncol. 2000 Oct;11(10):1349-51
pubmed: 11106126
J Immunother Cancer. 2018 Jan 03;6(1):1
pubmed: 29298730
J Clin Pharm Ther. 2005 Dec;30(6):623-5
pubmed: 16336296
Br J Haematol. 2020 Mar;188(5):732-735
pubmed: 31573682
Bull Cancer. 2019 Jan;106(1S):S102-S109
pubmed: 30661749
South Med J. 1994 Mar;87(3):409-11
pubmed: 8134869
Radiother Oncol. 1999 Jan;50(1):113-9
pubmed: 10225565
J Hematol Oncol. 2018 Dec 20;11(1):141
pubmed: 30572922
Front Oncol. 2021 May 20;11:670464
pubmed: 34094967
Lancet Oncol. 2009 Jul;10(7):718-26
pubmed: 19573801
Blood. 2014 Jul 10;124(2):188-95
pubmed: 24876563
Isr Med Assoc J. 2014 Jul;16(7):456-7
pubmed: 25167696
Am J Hematol. 1999 Jan;60(1):75-6
pubmed: 9883811
J Clin Oncol. 2008 Dec 20;26(36):6005-6
pubmed: 19029410
JAMA Oncol. 2021 Jul 1;7(7):1051-1059
pubmed: 33885725
Indian J Hematol Blood Transfus. 2017 Mar;33(1):41-44
pubmed: 28194054
J Pak Med Assoc. 1992 Aug;42(8):191-3
pubmed: 1433798
Br J Haematol. 2010 May;149(4):578-86
pubmed: 20331465
Radiat Med. 2004 Jan-Feb;22(1):52-5
pubmed: 15053177
Turk J Haematol. 2016 Sep 5;33(3):248-50
pubmed: 27093891
Ann Saudi Med. 2012 May-Jun;32(3):306-8
pubmed: 22588444
Med Pediatr Oncol. 1994;23(2):136-9
pubmed: 8202037
Br J Haematol. 2004 Oct;127(1):3-11
pubmed: 15384972
Postgrad Med. 2012 Mar;124(2):92-101
pubmed: 22437219
Am J Emerg Med. 2017 Jun;35(6):941.e3-941.e4
pubmed: 28132791